Toxicological risk assessment | Materials Metric

When developing a medical device or evaluating a new material for human contact, toxicological risk assessment (TRA) forms the scientific backbone of the entire safety evaluation process. At Materials Metric, we help engineers, scientists, and quality teams navigate this complex process with confidence. A TRA systematically identifies, characterizes, and quantifies potential chemical hazards in materials. Consequently, it gives regulatory reviewers the evidence they need to make sound safety decisions.

For medical device manufacturers in particular, toxicological risk assessment connects directly to biocompatibility testing under ISO 10993 and FDA guidance. Furthermore, without a rigorous TRA, companies risk costly test failures, submission delays, and patient safety concerns. Understanding what a TRA involves — and how to build one properly — is therefore essential for any team working with implantable, skin-contact, or mucosal-contact materials.

In addition, the increasing use of complex polymers, adhesives, coatings, and metal alloys in modern devices means chemical characterization data must feed directly into a structured risk framework. Moreover, regulatory agencies now expect manufacturers to justify their biocompatibility conclusions with quantitative toxicological data, not just pass/fail cytotoxicity results. This article explains what a TRA is, how it works, and how expert laboratory support can streamline the process significantly.

Key Takeaways

• A toxicological risk assessment (TRA) evaluates chemical hazards in materials intended for human contact, particularly medical devices.
• TRA is a required component of ISO 10993-1 biocompatibility evaluations and FDA 510(k) or PMA submissions.
• Chemical characterization data — including extractables, leachables, and elemental impurities — feeds directly into the TRA framework.
• Tolerable intake (TI) values and safety margins help toxicologists determine acceptable exposure levels for each identified chemical.
• A well-prepared TRA can reduce or eliminate the need for additional animal testing, saving time and resources.
• Expert laboratory partners like Materials Metric can provide the analytical data, method validation, and consulting support needed to complete a defensible TRA.

What Is Toxicological Risk Assessment in the Context of Medical Devices?

Toxicological risk assessment is a structured, science-based process for evaluating whether chemicals present in a material or device pose an unacceptable risk to patients or users. Specifically, it combines chemical characterization data with established toxicological thresholds to calculate safety margins. Regulatory bodies such as the FDA and ISO Technical Committee 194 require this process as part of a complete biocompatibility evaluation.

In practice, a TRA answers one fundamental question: do the chemicals identified in a device — at the doses patients may realistically encounter — cause harm? Therefore, the TRA is never just a literature review. It demands quantitative analytical data, sound exposure modeling, and sound toxicological judgment applied together.

Why TRA Matters for Biocompatibility Testing

Biocompatibility testing historically relied on a battery of in vivo and in vitro biological tests. However, regulatory guidance has evolved significantly over the past decade. ISO 10993-1:2018 now places chemical characterization and toxicological risk assessment at the center of the evaluation strategy. As a result, biological tests are increasingly triggered only when TRA findings indicate a residual risk that chemistry data alone cannot resolve.

This shift benefits manufacturers in several ways. First, it can reduce reliance on animal studies where chemical data provides sufficient safety assurance. Furthermore, it produces a more scientifically defensible submission. Teams that understand this shift can therefore design more efficient development programs from the start.

The Relationship Between TRA and Chemical Characterization

Chemical characterization generates the input data that a TRA requires. Specifically, extractables and leachables studies identify what chemicals a device releases under simulated or actual use conditions. Elemental impurities screening, organic chemical profiling, and residual solvent analysis all contribute critical data points. Without high-quality analytical data, a toxicologist simply cannot complete a credible risk assessment.

This is precisely why Chemical & Elemental Characterization services are so central to the TRA workflow. Moreover, the quality and completeness of the analytical data directly determine the strength of the toxicological conclusions. Consequently, investing in robust, method-validated analytical testing is never optional — it is foundational.

How Does the Toxicological Risk Assessment Process Work?

A toxicological risk assessment follows a logical, stepwise framework. Each step builds on the previous one, creating a traceable chain of evidence from chemical identification through to a final risk conclusion. Importantly, this framework aligns with guidance from ISO 10993-18 Chemical Characterization and FDA’s published recommendations on chemical characterization of medical devices.

Overall, the TRA process involves four core phases: hazard identification, dose-response assessment, exposure assessment, and risk characterization. Together, these phases produce a Margin of Safety (MOS) or Tolerable Intake (TI) comparison for each substance of concern. Let’s explore each phase in detail.

Phase 1 — Hazard Identification

Hazard identification determines what toxic properties a chemical possesses. Toxicologists search authoritative databases such as PubMed Central – Trace Metals Review and regulatory agency monographs for published toxicological data. They evaluate endpoints including cytotoxicity, genotoxicity, carcinogenicity, reproductive toxicity, and sensitization potential.

For chemicals lacking published data, toxicologists may apply structure-activity relationship (SAR) modeling or computational toxicology tools. However, whenever robust human or animal study data exists, that data takes priority. Notably, the completeness of the hazard profile directly influences how conservative the subsequent risk calculation must be.

Phase 2 — Dose-Response Assessment and Tolerable Intake

Dose-response assessment establishes the relationship between the amount of a chemical and the severity of its toxic effects. From this relationship, toxicologists derive a Tolerable Intake (TI) — the maximum daily dose considered safe for human exposure over a defined duration. The TI accounts for body weight, exposure route, and the duration of device contact (limited, prolonged, or permanent).

For carcinogenic or genotoxic substances, toxicologists instead apply a Threshold of Toxicological Concern (TTC) approach or a cancer risk model. Furthermore, for elemental impurities in drug products, established Permitted Daily Exposure (PDE) values from USP General Chapter <232> Elemental Impurities often serve as the benchmark. These established thresholds streamline the assessment for common inorganic chemicals significantly.

Phase 3 — Exposure Assessment

Exposure assessment calculates the actual dose a patient or user receives from the device. Specifically, this involves multiplying the concentration of each leachable chemical by the estimated daily contact area, extraction volume, or dose per use. Duration and frequency of use also factor into the calculation directly.

This phase depends entirely on reliable, quantitative analytical data. For example, an implantable device with a 10-year service life requires a very different exposure model than a single-use surgical instrument. Therefore, the analytical testing protocol must reflect realistic worst-case exposure scenarios. Chemical & Analytical Testing services tailored to device-specific use conditions produce the most defensible exposure inputs.

Phase 4 — Risk Characterization and Margin of Safety

Risk characterization brings all previous phases together. The toxicologist compares the calculated patient exposure dose to the established TI or TTC for each chemical. This comparison yields a Margin of Safety (MOS). An MOS greater than one indicates that the estimated exposure falls below the level of concern — meaning the chemical poses an acceptable risk.

In addition, the risk characterization narrative must address uncertainty factors, data gaps, and any worst-case assumptions used. Regulatory reviewers look for transparent, well-documented reasoning at every step. Consequently, a clearly written TRA report — supported by traceable analytical data — significantly strengthens a submission’s chances of acceptance.

Key Data Inputs Required for a Robust Toxicological Risk Assessment

A TRA is only as strong as the analytical data supporting it. Regulators increasingly scrutinize not just the toxicological conclusions but also the quality, specificity, and traceability of the underlying chemical data. Therefore, selecting the right analytical methods — and validating them properly — is a prerequisite for a defensible TRA.

Several categories of analytical data feed into a typical medical device TRA. Each category addresses a different class of potential chemical hazard. Moreover, the choice of methods must reflect the material types, device geometry, and intended use conditions specific to the product being evaluated.

Extractables and Leachables Profiling

Extractables studies expose device materials to aggressive solvents under exaggerated conditions to identify the full chemical inventory. Leachables studies then simulate realistic use conditions to determine what actually migrates into patient contact under normal circumstances. Together, these studies define the chemical universe that the TRA must evaluate.

Analytical techniques such as GC-MS, LC-MS/MS, ICP-MS, and headspace analysis all play roles in comprehensive E&L profiling. Furthermore, Chemical Purity & Contaminant Screening adds another layer of assurance by detecting unexpected impurities or contaminants introduced during manufacturing. Notably, a thorough E&L dataset dramatically reduces the toxicological uncertainty in downstream risk calculations.

Elemental Impurities and Trace Metal Analysis

Metal components, pigments, catalysts, and processing aids can all introduce elemental impurities into medical device materials. For devices with drug delivery functions, the requirements of ICH Q3D and USP <232>/<233> apply directly. Even for non-drug devices, elemental characterization remains a critical input to the TRA for any material containing metals, metal oxides, or inorganic fillers.

ICP-OES and ICP-MS deliver the ultra-trace sensitivity needed to detect elements at parts-per-billion concentrations. In addition, techniques like SEM Analysis and XRD Analysis can help characterize particle morphology and crystalline phase — both of which influence the bioavailability and toxicological relevance of inorganic materials. Consequently, multi-technique elemental characterization provides a far more complete hazard picture than any single method alone.

Organic Chemical Profiling and Residual Solvents

Polymers and adhesives used in medical devices often contain plasticizers, antioxidants, UV stabilizers, and residual monomers. Similarly, manufacturing processes introduce residual solvents that may persist in the final product. Each of these organic chemicals requires identification and quantification before a toxicologist can assess its risk.

Techniques such as FTIR Analysis and DSC Testing support material identification and thermal profiling. Moreover, GC-MS and NMR spectroscopy provide the molecular-level identification needed for organic leachables. Specifically, any chemical detected above the Analytical Evaluation Threshold (AET) must receive full toxicological evaluation within the TRA framework.

Method Development and Validation for TRA Inputs

Analytical data used in a regulatory submission must come from validated methods. Specifically, method validation confirms that the analytical procedure is accurate, precise, specific, and reproducible at the concentration levels relevant to the TRA. Without validated methods, regulators may reject the analytical data entirely — invalidating the entire risk assessment.

Proper Method Development & Validation ensures that detection limits, quantitation limits, and matrix effects are fully characterized and documented. Furthermore, validated methods give toxicologists confidence that the reported concentrations accurately reflect real-world leachable levels. As a result, method validation is never a bureaucratic formality — it is a scientific necessity that directly protects the integrity of the TRA.

Toxicological Risk Assessment Across Industry Applications

Toxicological risk assessment applies broadly across multiple regulated industries. However, the specific requirements, thresholds, and regulatory frameworks vary considerably by sector. Understanding these differences helps teams tailor their TRA approach to their exact context. Furthermore, a well-scoped TRA avoids both under-evaluation and unnecessary over-testing.

Medical Devices and Implantable Materials

Medical devices represent the most demanding application of toxicological risk assessment. Implantable devices, in particular, require permanent-contact exposure modeling and strict MOS calculations. Regulatory submissions to the FDA or Notified Bodies under the EU MDR must include a complete TRA as part of the biocompatibility evaluation file.

Specifically, Biocompatibility & Toxicity Testing integrates directly with the TRA workflow for medical devices. Moreover, for devices that have undergone design changes or material substitutions, a gap analysis TRA can determine whether new testing is necessary. Consequently, manufacturers save significant time by addressing chemical risks early in product development rather than at submission.

Pharmaceutical Packaging and Drug-Device Combination Products

Pharmaceutical packaging materials can leach chemicals into drug formulations over shelf life. Therefore, container closure integrity and extractables testing are regulatory requirements for primary packaging components. For drug-device combination products — such as prefilled syringes or inhalers — both ICH Q3B leachables guidance and ISO 10993 apply simultaneously.

In these cases, the TRA must evaluate leachable chemicals against both drug-product patient exposure limits and device biocompatibility thresholds. Additionally, USP Elemental Impurities standards provide established PDE values that anchor the elemental portion of the assessment. Notably, this dual-standard environment demands highly experienced toxicologists who understand both regulatory frameworks.

Aerospace, Electronics, and Consumer Products

Beyond healthcare, toxicological risk assessment informs chemical safety evaluations in aerospace materials, electronics coatings, and consumer goods. For example, aerospace composites may contain epoxy resins, flame retardants, and nanomaterials that require chemical hazard profiling. Similarly, consumer product regulations such as REACH and RoHS mandate substance restriction compliance supported by analytical data.

In these sectors, TRA principles remain the same even though the regulatory endpoints differ. Furthermore, Chemical & Elemental Characterization supports restricted substance screening across all these applications. As a result, the TRA framework translates efficiently from healthcare into any industry where material chemistry affects human safety.

Quality Assurance and Best Practices in Toxicological Risk Assessment

A rigorous quality framework underpins every defensible toxicological risk assessment. Regulators do not simply evaluate conclusions — they scrutinize the entire evidence chain, from sample preparation through to risk characterization. Consequently, quality assurance must be embedded throughout the TRA process, not applied as a final review step.

Documentation, Traceability, and Version Control

Every analytical result feeding into a TRA must be fully traceable to its source. This means laboratory notebooks, instrument records, calibration logs, and chain-of-custody documentation must all be maintained meticulously. Furthermore, the TRA report itself should reference specific analytical data files, method validation records, and toxicological literature sources by version and date.

Regulatory reviewers frequently request supporting raw data during pre-submission meetings or audits. Therefore, organizing and preserving this documentation from the start prevents costly delays later. Notably, electronic laboratory management systems (LIMS) significantly improve traceability for complex, multi-analyte TRA datasets.

Selecting Qualified Toxicologists and Analytical Partners

The strength of a TRA depends directly on the expertise of the people who write and review it. Specifically, the toxicological narrative must reflect current regulatory guidance, up-to-date scientific literature, and sound professional judgment. Regulatory agencies expect the TRA to be authored or reviewed by a qualified toxicologist with relevant training and experience.

Equally important is selecting an analytical laboratory with validated methods, appropriate accreditations, and experience in medical device or pharmaceutical testing. For instance, Scientific & Technical Consulting from Materials Metric bridges the gap between raw analytical data and regulatory-grade toxicological documentation. Moreover, an integrated partner who handles both testing and consulting eliminates costly miscommunications between separate service providers.

Applying Conservative Assumptions and Uncertainty Factors

Good toxicological practice requires acknowledging uncertainty transparently. When robust toxicological data is unavailable for a specific chemical, toxicologists apply uncertainty factors (UFs) to derive conservative TI values. For example, an interspecies uncertainty factor of 10 and an intraspecies factor of 10 together yield a combined UF of 100 — a standard default in many risk frameworks.

Additionally, worst-case exposure assumptions protect patients when real-world use patterns are highly variable. However, excessive conservatism can trigger unnecessary additional testing. Therefore, the goal is always a scientifically justified, proportionate risk assessment — not one that is artificially restrictive without evidence-based reason.

Quick Note: A Margin of Safety (MOS) greater than 1.0 signals that estimated patient exposure falls below the toxicological threshold of concern. However, many regulatory reviewers expect an MOS of 100 or greater before concluding that a chemical poses negligible risk — particularly for permanent-contact implants. Always confirm applicable MOS expectations with your regulatory consultant before finalizing the TRA.

How Materials Metric Supports Your Toxicological Risk Assessment

Building a defensible toxicological risk assessment requires both high-quality analytical data and expert scientific interpretation. Materials Metric delivers both capabilities under one roof, supporting medical device manufacturers, pharmaceutical companies, and material suppliers throughout the entire TRA workflow.

Integrated Analytical and Consulting Services

Materials Metric provides comprehensive Chemical & Analytical Testing services designed specifically to generate TRA-ready data. Furthermore, our teams understand the regulatory context of every test they perform — so data packages arrive formatted for direct use in toxicological evaluations. This integration reduces turnaround time and minimizes the risk of data gaps that could delay a submission.

In addition, our Method Development & Validation capabilities ensure that every analytical procedure meets the specificity and sensitivity requirements of your TRA. Consequently, you can enter the regulatory review process with full confidence in your underlying chemical data. Moreover, our validated methods satisfy FDA, ISO, and ICH requirements across a wide range of material types and device categories.

From Chemical Data to Regulatory Documentation

Raw analytical numbers alone do not constitute a TRA. Specifically, a complete submission-ready TRA requires a written toxicological risk assessment report that interprets the data within the applicable regulatory framework. Materials Metric’s Scientific & Technical Consulting team supports clients in preparing these reports for ISO 10993-18 and FDA chemical characterization review submissions.

For additional context on FDA’s expectations, our published resource on FDA chemical characterization review outlines what reviewers look for in a well-structured chemical safety package. Furthermore, research published through ScienceDirect continues to advance analytical methods that directly improve TRA data quality. By staying current with evolving science, Materials Metric helps clients maintain regulatory readiness even as standards evolve.

Biocompatibility Testing Integrated With TRA Findings

When TRA findings identify residual risks that chemistry data alone cannot resolve, biological testing becomes necessary. In those situations, our Biocompatibility & Toxicity Testing services provide the next line of evidence. These include cytotoxicity, sensitization, irritation, and systemic toxicity studies aligned with ISO 10993 test standards.

By integrating TRA findings with targeted biological testing, manufacturers avoid unnecessary testing while still meeting all regulatory requirements. Additionally, this integrated approach produces a coherent, science-driven biocompatibility evaluation that reviewers find easier to assess and accept. Ultimately, the goal is a complete, well-supported safety file — not simply a collection of test reports.

Comparison: TRA-Led vs. Traditional Biocompatibility Testing Approaches

The table below compares the traditional battery-based biocompatibility approach with a modern TRA-led evaluation strategy. Understanding these differences helps teams make informed decisions about their testing and submission plans.

Frequently Asked Questions About Toxicological Risk Assessment

What is the difference between a TRA and a biocompatibility evaluation?

A biocompatibility evaluation is the overall process of determining whether a device is safe for human contact. Toxicological risk assessment is one critical component within that evaluation. Specifically, the TRA uses chemical characterization data to calculate safety margins, while the broader biocompatibility evaluation may also include biological testing, clinical data, and literature review.

Is a toxicological risk assessment required for all medical devices?

Under ISO 10993-1:2018, all devices that contact patients or users require a biocompatibility evaluation, which includes a TRA. However, the depth of the TRA scales with the nature and duration of device contact. For example, a permanent implant requires a far more extensive TRA than a brief, non-contact device. Consequently, risk-based scoping of the TRA is both permitted and encouraged by regulators.

How long does a toxicological risk assessment take to complete?

Timeline depends on data availability, material complexity, and the need for new analytical testing. If validated analytical data already exists, an experienced toxicologist may complete a TRA report in two to four weeks. However, if new extractables or leachables studies are required first, the overall timeline can extend to several months. Therefore, starting the TRA process early in device development is strongly advisable.

What happens if the TRA identifies a chemical with an unacceptable risk?

An unfavorable TRA finding does not necessarily mean a device fails. Instead, it triggers a risk mitigation review. Options include reformulating the material, changing manufacturing processes, applying additional purification steps, or conducting targeted biological testing for the specific endpoint of concern. Furthermore, ISO 10993-18 guidance supports iterative risk management where identified hazards drive specific, proportionate responses.

Can a TRA replace animal testing entirely?

In many cases, a well-supported TRA can eliminate the need for specific animal studies. For instance, if the TRA demonstrates that all leachable chemicals fall well below their TI values, cytotoxicity or systemic toxicity tests may be unnecessary. However, some endpoints — such as sensitization for novel materials — may still require biological confirmation. Overall, the TRA-led approach maximizes the replacement of animal tests wherever sound science permits.

What analytical methods does Materials Metric use to support TRA studies?

Materials Metric employs a broad range of validated analytical techniques tailored to TRA data requirements. These include ICP-MS and ICP-OES for elemental impurities, GC-MS and LC-MS/MS for organic leachables, and FTIR for material identification. Additionally, our Chemical & Analytical Testing team selects and validates the most appropriate methods for your specific device materials and regulatory context. All methods comply with relevant ISO, FDA, and ICH standards.

Conclusion

Toxicological risk assessment is no longer an optional add-on to medical device development — it is the scientific foundation on which modern biocompatibility evaluations rest. Furthermore, regulatory agencies worldwide increasingly demand quantitative, chemistry-driven safety justifications rather than simple pass/fail test results. Consequently, teams that invest in high-quality analytical data and expert toxicological interpretation gain a significant competitive advantage in the regulatory process.

Building a defensible TRA requires the right analytical data, validated methods, experienced toxicologists, and a clear understanding of current regulatory expectations. Moreover, integrating chemical characterization, exposure modeling, and risk characterization into a single cohesive document demands strong coordination between laboratory scientists and regulatory consultants. Therefore, choosing a partner with capabilities across all these disciplines is essential for success.

Materials Metric provides the full range of analytical, validation, and consulting services needed to support every stage of the toxicological risk assessment process. From elemental impurities screening through to final TRA report preparation, our team delivers the scientific rigor and regulatory knowledge your submission requires. Ultimately, our goal is to help you bring safe, well-characterized devices to market — efficiently, confidently, and with the documentation to support it.

Ready to start your toxicological risk assessment? Contact Materials Metric today to discuss your specific device materials, regulatory timeline, and analytical testing needs. Our scientific team welcomes the opportunity to help you build a complete, defensible chemical safety package from the ground up.

Related Posts from Materials Metric

Explore more insights from our team of materials scientists and analytical experts:

• FDA chemical characterization review | Materials Metric
• Biological evaluation plan | Materials Metric | Compliance
• ISO 10993-1:2025 changes | Materials Metric | Compliance
• Trace Metal Analysis Services: Methods, Applications, and Regulatory Considerations